Arcturus Therapeutics Holdings Inc. Form 4 (Dec. 7, 2021)

Summary

A Form 4 for Arcturus Therapeutics Holdings Inc. filed by director Marantz Jing L. and signed /s/ Jing L. Marantz on December 9, 2021. It reports stock options (right to buy) dated December 7, 2021 at $38.54, each expiring December 6, 2031. The option for 20,000 shares is described as the initial grant to the Reporting Person as a member of the Board, vesting monthly over a two year period. The option for 6,699 shares is the annual grant, prorated based on the appointment date to represent an estimated six months of service, vesting monthly over a one year period.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Marantz Jing L. (Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS HOLDINGS INC. 10628 SCIENCE CENTER DRIVE, SUITE 250 (Street) SAN DIEGO CA 2121 (City) (State) (Zip) | Marantz Jing L. | (Last) | (First) | (Middle) | C/O ARCTURUS THERAPEUTICS HOLDINGS INC. | 10628 SCIENCE CENTER DRIVE, SUITE 250 | SAN DIEGO | CA | 2121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ ARCT ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 12/07/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock option (right to buy) | $ 38.54 | 12/07/2021 | A | 20,000 | (1) | 12/06/2031 | Common Stock | 20,000 | $ 0.00 | 20,000 | D
Stock option (right to buy) | $ 38.54 | 12/07/2021 | A | 6,699 | (2) | 12/06/2031 | Common Stock | 6,699 | $ 0.00 | 6,699 | D
Explanation of Responses:
1. Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors (the "Board").
2. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board, representing an estimated six months of service.
/s/ Jing L. Marantz | 12/09/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_ARCT_4_filed2021-12-09_0001193805-21-001718.xml

Size

16,912 bytes

SHA-256

ceacc9171cd2ad83625cfc48d3de9c6add49b87565fe3cc1a377f0c256c1e355

Our copy

SEC_ARCT_4_filed2021-12-09_0001193805-21-001718.xml

Original

www.sec.gov